You just read:

Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications

News provided by

Can-Fite BioPharma Ltd.

Dec 19, 2013, 07:00 ET